Pharmaceutical Technology, Jun 2, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Jun 2, 2011
Special Report
Next-Gen Expression Systems
By Amy Ritter
More sophisticated biological expression systems expand the functionality of the traditional systems for protein synthesis.
The Means to Monitor Chemical Migration
By Erik Greb
Industry associations will soon provide new recommendations about extractables and leachables.
Special Feature
Prevention of Microbial Contamination
By Elaine Kopis Sartain , Jim Polarine
A holistic approach to establishing robust control measures.
Peer-Reviewed Research
Inhibiting the Precipitation of Poorly Water-Soluble Drugs from Labrasol Formulations
By Wei-Guo Dai , Liang C. Dong , Abla A. Creasey
The study results suggested that Pluronic F127 might be a potent inhibitor of drug precipitation for Labrasol formulations.
A Comparison of Three Extrusion Systems (Part II)
By Amelie Desire , Bruno Paillard , Joel Bougaret , Michel Baron , Guy Couarraze
The authors compare three systems of single-screw extrusion using binary formulations for their suitability for producing pellets of various formulations and under various spheronization conditions.
Guest Editorial
Policy and Leadership
By Jim Greenwood
This month's BIO Convention will encourage needed conversations.
PharmTech Talk
The Pediatric Challenge
By Stephanie Sutton
Can microdosing make medicines safer and more effective for children?
Agent-in Place
Quality Overload
By Control, a senior compliance officer
Sometimes, there are just too many cooks in the kitchen.
News
Report from India
By A. Nair
India's drug pricing authority increased the retail costs of certain domestically manufactured drugs, but not those of imported drug products. Pharma is asking why.
Global Healthcare on the Ground: BIO and BIO Ventures for Global Health
By Christina I. Ortiz , Angie Drakulich
A Focus on Creative Strategies to Help the Developing World.
In the Spotlight
In the Spotlight
Editor's picks of new manufacturing products for June 2011.
Washington Report
Safety Concerns and Shortages Challenge Pharma
By Jill Wechsler
Industry struggles to curb drug abuse, diversion, and disruptions in supply.
BioForum
21st Century Innovation
By Kenneth I. Kaitin
Academic–industry partnerships are increasingly important in biopharmaceutical innovation.
Statistical Solutions
Statistics in the Service of Quality
By Lynn D. Torbeck
Ensuring compliance though increased statistical knowledge and resources.
Pharma Ingredients
Optimizing High-Potency Manufacturing
By Patricia Van Arnum
Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.
Outsourcing Outlook
Wanted: Better Upstream Bioprocessing Technologies
By Eric Langer
A recent industry survey shows keen interest in improving bioreactors and cell-culture media.
Insider Solutions
Following our Own Instructions
By Susan J. Schniepp
Why SOPs are rarely followed, often cited, and in need of follow-through.
Industry Leader
Q&A with Christopher Meissner, Meissner
Christopher Meissner, CEO of Meissner Filtration Products, on recent industry trends.
Viewpoint
Advocating for Biosimilar Approval Standards Under BPCI
By Chad A. Landmon , Elizabeth P. Retersdorf
FDA weighs multiple views regarding the Biologics Price Competition and Innovation Act.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
8%
All of the above.
41%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here